Arcutis Biotherapeutics Inc
NASDAQ:ARQT

Watchlist Manager
Arcutis Biotherapeutics Inc Logo
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Watchlist
Price: 13.16 USD -2.52%
Market Cap: 1.6B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+65%
Revenue
Forecast
+6%
Operating Income
Forecast
+37%
Net Income
Forecast
+24%

Wall Street
Price Targets

ARQT Price Targets Summary
Arcutis Biotherapeutics Inc

Wall Street analysts forecast ARQT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARQT is 21.57 USD with a low forecast of 19.19 USD and a high forecast of 30.45 USD.

ARQT Lowest Forecast
Wall Street Target
19.19 USD
46% Upside
ARQT Average Forecast
Wall Street Target
21.57 USD
64% Upside
ARQT Highest Forecast
Wall Street Target
30.45 USD
131% Upside
Lowest
Price Target
19.19 USD
46% Upside
Average
Price Target
21.57 USD
64% Upside
Highest
Price Target
30.45 USD
131% Upside
Arcutis Biotherapeutics Inc Competitors:
Price Targets
300653
Yantai Zhenghai Bio-Tech Co Ltd
37% Upside
688177
Bio-Thera Solutions Ltd
3% Downside
DSGN
Design Therapeutics Inc
91% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
24% Downside
300653
Yantai Zhenghai Bio-Tech Co Ltd
37% Upside
688177
Bio-Thera Solutions Ltd
3% Downside
DSGN
Design Therapeutics Inc
91% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
24% Downside
ACAD
ACADIA Pharmaceuticals Inc
25% Upside
REGN
Regeneron Pharmaceuticals Inc
50% Upside
C
2487
Cutia Therapeutics
10% Downside
MNKD
MannKind Corp
174% Upside

Revenue
Forecast

Revenue Estimate
Arcutis Biotherapeutics Inc

The compound annual growth rate of Arcutis Biotherapeutics Inc's revenue for the next 3 years is 45%.

N/A
Past Growth
45%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Arcutis Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Arcutis Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-58%
Average Miss
What are analyst estimates?

See Also

Summary
ARQT intrinsic value, competitors valuation, and company profile.
DCF Valuation
ARQT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ARQT stock valuation using valuation multiples.
Wall Street Estimates
ARQT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ARQT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ARQT's stock price target?
Price Target
21.57 USD

According to Wall Street analysts, the average 1-year price target for ARQT is 21.57 USD with a low forecast of 19.19 USD and a high forecast of 30.45 USD.

What is Arcutis Biotherapeutics Inc's Revenue forecast?
Projected CAGR
45%

The compound annual growth rate of Arcutis Biotherapeutics Inc's revenue for the next 3 years is 45%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 261,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.